Literature DB >> 24704113

Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Jianming Pei1, Valentin Robu2, Madelyn Feder3, Mitchell Cheung4, Erin Neumann-Domer3, Jacqueline Talarchek4, Essel Dulaimi2, Michael M Millenson5, Joseph R Testa6.   

Abstract

Single nucleotide polymorphism (SNP)-based chromosome microarray analysis was used to uncover copy neutral loss of heterozygosity (LOH) in the long arm of chromosome 20 in blood or bone marrow specimens from three patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). All three patients presented with lymph node enlargement. Whereas one of the patients has had a complicated clinical course, the other two have a more indolent disease. Sequence analysis of the tumor suppressor gene ASXL1, which is located in 20q and is commonly mutated in malignant myeloid diseases and occasionally in CLL/SLL specimens, revealed no mutations in our three patients with copy neutral LOH in 20q. The possible contribution of other imprinted microRNAs and antisense genes residing in 20q to the pathogenesis of a subset of CLL/SLL patients is discussed. These findings illustrate the value of SNP arrays for the detection of novel recurrent genomic alterations that may contribute to CLL/SLL onset or progression.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic lymphocytic leukemia; chromosome 20; chromosome microarray analysis; copy neutral loss of heterozygosity; imprinting

Mesh:

Year:  2014        PMID: 24704113      PMCID: PMC4010307          DOI: 10.1016/j.cancergen.2014.02.005

Source DB:  PubMed          Journal:  Cancer Genet


  32 in total

Review 1.  GNAS locus and pseudohypoparathyroidism.

Authors:  Murat Bastepe; Harald Jüppner
Journal:  Horm Res       Date:  2005-02-09

2.  Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays.

Authors:  Jill M Hagenkord; Federico A Monzon; Shera F Kash; Stan Lilleberg; Qingmei Xie; Jeffrey A Kant
Journal:  J Mol Diagn       Date:  2010-01-14       Impact factor: 5.568

3.  Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients.

Authors:  R Gunnarsson; A Isaksson; M Mansouri; H Göransson; M Jansson; N Cahill; M Rasmussen; J Staaf; J Lundin; S Norin; A M Buhl; K E Smedby; H Hjalgrim; K Karlsson; J Jurlander; G Juliusson; R Rosenquist
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

4.  Delineation of individual human chromosomes in metaphase and interphase cells by in situ suppression hybridization using recombinant DNA libraries.

Authors:  P Lichter; T Cremer; J Borden; L Manuelidis; D C Ward
Journal:  Hum Genet       Date:  1988-11       Impact factor: 4.132

5.  Implementation of high resolution single nucleotide polymorphism array analysis as a clinical test for patients with hematologic malignancies.

Authors:  Margaret J Dougherty; Donna M Wilmoth; Laura S Tooke; Tamim H Shaikh; Xiaowu Gai; Hakon Hakonarson; Jaclyn A Biegel
Journal:  Cancer Genet       Date:  2011-01

6.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Calin Dan Dumitru; Masayoshi Shimizu; Roberta Bichi; Simona Zupo; Evan Noch; Hansjuerg Aldler; Sashi Rattan; Michael Keating; Kanti Rai; Laura Rassenti; Thomas Kipps; Massimo Negrini; Florencia Bullrich; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

7.  TP53 mutation and survival in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Barbara Eichhorst; Raymonde Busch; Tina Denzel; Sonja Häbe; Dirk Winkler; Andreas Bühler; Jennifer Edelmann; Manuela Bergmann; Georg Hopfinger; Manfred Hensel; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

8.  High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.

Authors:  Jennifer Edelmann; Karlheinz Holzmann; Florian Miller; Dirk Winkler; Andreas Bühler; Thorsten Zenz; Lars Bullinger; Michael W M Kühn; Andreas Gerhardinger; Johannes Bloehdorn; Ina Radtke; Xiaoping Su; Jing Ma; Stanley Pounds; Michael Hallek; Peter Lichter; Jan Korbel; Raymonde Busch; Daniel Mertens; James R Downing; Stephan Stilgenbauer; Hartmut Döhner
Journal:  Blood       Date:  2012-10-09       Impact factor: 22.113

9.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

10.  TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p.

Authors:  M Jasek; L P Gondek; N Bejanyan; R Tiu; J Huh; K S Theil; C O'Keefe; M A McDevitt; J P Maciejewski
Journal:  Leukemia       Date:  2009-09-17       Impact factor: 11.528

View more
  2 in total

1.  The effects of miR-1207-5p expression in peripheral blood on cisplatin-based chemosensitivity of primary gallbladder carcinoma.

Authors:  Er-Dong Shen; Bo Liu; Xin-Shuang Yu; Zhen-Fei Xiang; Hui-Yun Huang
Journal:  Onco Targets Ther       Date:  2016-06-20       Impact factor: 4.147

2.  Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells.

Authors:  C Cameron Yin; Guilin Tang; Gary Lu; Xiaoli Feng; Michael J Keating; L Jeffrey Medeiros; Lynne V Abruzzo
Journal:  Mod Pathol       Date:  2015-05-08       Impact factor: 7.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.